Ermaft 0,75 mg/1,5 mg Tablets
PDF Leaflet Revision Date: 26 October 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Emergency contraception within 72 hours of unprotected intercourse.
Dosage (summary)
ERMAFT 0.75 mg: 2 tablets; ERMAFT 1.5 mg: 1 tablet, taken as soon as possible within 72 hours.
Special Populations
- Not recommended in children
- Obese women may have reduced efficacy
Pregnancy & Breastfeeding
Not for use in pregnancy; minimal transfer in breast milk; avoid nursing for 6 hours post-dose.
Key Drug Interactions
- CYP3A4 inducers (e.g., efavirenz, rifampicin)
- Anticonvulsants (e.g., phenytoin)
- St. John's wort
Contraindications
- Hypersensitivity to levonorgestrel
- Severe hepatic insufficiency
- Pregnancy
- Undiagnosed vaginal bleeding
- Uncontrolled depression
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Menstrual changes
Counselling Points
- Use as soon as possible after unprotected intercourse
- Consult a healthcare provider if no period occurs after 5 days
- Consider regular contraception after use
Serious warnings
- Not a regular contraceptive method
- Risk of ectopic pregnancy
- Mood changes and depression
Important Disclaimer
The Ermaft 0,75 mg/1,5 mg Tablets professional information leaflet below is the property of Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
